Cargando…

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin

BACKGROUND: Rezafungin (RZF) is a novel echinocandin antifungal being developed for treatment of candidemia and invasive candidiasis, and for prevention of invasive fungal diseases among immunosuppressed patients. In the Phase 2 and Phase 3 treatment trials of rezafungin compared with caspofungin (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huguet, Jade, Ong, Voon, Sandison, Taylor, Melara, Rebeca M, Marbury, Thomas C, Jandourek, Alena, Flanagan, Shawn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643917/ http://dx.doi.org/10.1093/ofid/ofab466.1176

Ejemplares similares

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
por: Gu, Kenan, et al.
Publicado: (2022)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
por: Sandison, Taylor, et al.
Publicado: (2017)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
por: Marbury, Thomas, et al.
Publicado: (2017)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
por: Hossain, Mohammad, et al.
Publicado: (2021)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

IS982 and kin: new insights into an old IS family
por: Fayad, Nancy, et al.
Publicado: (2020)

722. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Hepatic Function
por: Wicha, Wolfgang, et al.
Publicado: (2019)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
por: Gao, Ling, et al.
Publicado: (2023)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

2514. Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza
por: Flanagan, Shawn, et al.
Publicado: (2023)

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
por: Marbury, Thomas, et al.
Publicado: (2023)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17bu3a3h5crrvhpscuheekq7vb